Author

K.H.N. (Nanne) de Boer

MERCAPTOPURINE TREATMENT USING THERAPEUTIC DRUG MONITORING IS EFFECTIVE IN ULCERATIVE COLITIS: A PLACEBO-CONTROLLED RANDOMIZED TRIAL
MERCAPTOPURINE TREATMENT USING THERAPEUTIC DRUG MONITORING IS EFFECTIVE IN ULCERATIVE COLITIS: A PLACEBO-CONTROLLED RANDOMIZED TRIAL

K.H.N. (Nanne) de Boer  et al.

REAL-LIFE EXPERIENCE OF ANTI-DRUG ANTIBODIES AGAINST ANTI-TNF AGENTS AT TWO TERTIARY CARE PAEDIATRIC INFLAMMATORY BOWEL DISEASE CENTRES
REAL-LIFE EXPERIENCE OF ANTI-DRUG ANTIBODIES AGAINST ANTI-TNF AGENTS AT TWO TERTIARY CARE PAEDIATRIC INFLAMMATORY BOWEL DISEASE CENTRES

K.H.N. (Nanne) de Boer  et al.

SUPERIOR EFFECTIVENESS OF TOFACITINIB COMPARED TO VEDOLIZUMAB IN ANTI-TNF EXPERIENCED ULCERATIVE COLITIS PATIENTS: A NATIONWIDE DUTCH REGISTRY STUDY
SUPERIOR EFFECTIVENESS OF TOFACITINIB COMPARED TO VEDOLIZUMAB IN ANTI-TNF EXPERIENCED ULCERATIVE COLITIS PATIENTS: A NATIONWIDE DUTCH REGISTRY STUDY

K.H.N. (Nanne) de Boer  et al.

COST-EFFECTIVENESS ANALYSIS OF INCREASED ADALIMUMAB DOSE INTERVALS IN PATIENTS WITH CROHN’S DISEASE IN STABLE REMISSION: ECONOMIC EVALUATION OF THE RANDOMISED CONTROLLED LADI TRIAL
COST-EFFECTIVENESS ANALYSIS OF INCREASED ADALIMUMAB DOSE INTERVALS IN PATIENTS WITH CROHN’S DISEASE IN STABLE REMISSION: ECONOMIC EVALUATION OF THE RANDOMISED CONTROLLED LADI TRIAL

K.H.N. (Nanne) de Boer  et al.

CLINICAL OUTCOMES OF INCREASED VERSUS CONVENTIONAL ADALIMUMAB DOSE INTERVALS IN PATIENTS WITH CROHN’S DISEASE IN STABLE REMISSION: THE RANDOMISED CONTROLLED LADI TRIAL
CLINICAL OUTCOMES OF INCREASED VERSUS CONVENTIONAL ADALIMUMAB DOSE INTERVALS IN PATIENTS WITH CROHN’S DISEASE IN STABLE REMISSION: THE RANDOMISED CONTROLLED LADI TRIAL

K.H.N. (Nanne) de Boer  et al.

Item 1 - 5 / 5
1